Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

References

• Morse M. Technology evaluation: Ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther. 2005;7(6):588–97. PMID:16370382.
   PubMedGoogle Scholar
• Cameron F, Whiteside G, Perry C. Ipilimumab: First global approval. Drugs. 2011;71(8):2079–89. doi:10.2165/11594010-000000000-00000. PMID:21985171.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.0000000000000239. PMID:26558876.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Day SJO, Mcdermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved Survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466. PMID:20525992.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013;24(8):2174–80. doi:10.1093/annonc/mdt161. PMID:23666915.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother. 2013;62(6):1021–8. doi:10.1007/s00262-013-1418-6. PMID:23591982.
   PubMed Web of Science ®Google Scholar
• McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013;24(10):2694–8. doi:10.1093/annonc/mdt291. PMID:23942774.
   PubMed Web of Science ®Google Scholar
• Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane IM. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology. 2015;5(4):e1100788. doi:10.1080/2162402X.2015.1100788. PMID:27141381.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother. 2011;60(4):467–77. doi:10.1007/s00262-010-0958-2. PMID:21170646.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med. 2014;371(23):2189–99. doi:10.1056/NEJMoa1406498. PMID:25409260.
   PubMed Web of Science ®Google Scholar
• Daud AI, Loo K, Pauli ML, Sanchez-rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, et al. Tumor immune profiling predicts response to anti – PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):1–6. doi:10.1172/JCI87324.
   Web of Science ®Google Scholar
• Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19(14):3977–86. doi:10.1158/1078-0432.CCR-12-3243. PMID:23741070.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64. doi:10.1016/S1470-2045(09)70334-1. PMID:20004617.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5):611–22. doi:10.1016/S1470-2045(17)30231-0. PMID:28359784.
   PubMed Web of Science ®Google Scholar
• Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3–10. doi:10.1016/j.ymeth.2005.01.001. PMID:15848070.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Nencini F, Pratesi S, Petroni G, Maggi E, Matucci A. Manifestations of antidrug antibodies response: Hypersensitivity and infusion reactions. J Interf Cytokine Res. 2014;34(12):946–52. doi:10.1089/jir.2012.0139.
   PubMed Web of Science ®Google Scholar
• Radstake T, Svenson M, Eijsbouts AM, van den Hoogen FHJ, Enevold C, van Riel PLCM, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1739–45. doi:10.1136/ard.2008.092833. PMID:19019895.
   PubMed Web of Science ®Google Scholar
• West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, Van Der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28(9):1122–6. doi:10.1111/j.1365-2036.2008.03828.x. PMID:18691349.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601–8. doi:10.1056/NEJMoa020888. PMID:12584368.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54(12):3782–9. doi:10.1002/art.22214. PMID:17133559.
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109–17. doi:10.1056/NEJMoa074943. PMID:18337601.
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Aarden LA, Dijkmans B. Dealing with immunogenicity of biologicals: Assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3):211–5. doi:10.1097/BOR.0b013e328329ed8b. PMID:19399992.
   PubMed Web of Science ®Google Scholar
• FDA. Yervoy (ipilimumab) label [Internet]; 2013. Available from: http://www.accessdata.fda.gov/
   Google Scholar
• European Medicines Agency. EPAR Yervoy [Internet]; 2011. Available from: http://www.ema.europa.eu
   Google Scholar
• Agrawal S, Statkevich P, Bajaj G, Feng Y, Saeger S, Desai DD, Park JS, Waxman IM, Roy A, Gupta M. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J Clin Pharmacol. 2016;0(0):1–7.
   Google Scholar
• Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol. 2007;25(5):555–61. doi:10.1038/nbt1303. PMID:17483842.
   PubMed Web of Science ®Google Scholar
• Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler J. 2013 Apr 19;19(5):593–600. doi:10.1177/1352458512460604.
   PubMed Web of Science ®Google Scholar
• Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Mult Scler J. 2017;23(2):1–10.
   Google Scholar
• Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;6736(17):1–10.
   Google Scholar
• Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, Picard O, Chowers Y, Eliakim R, Ben-Horin S. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis. 2012;18(9):1628–33. doi:10.1002/ibd.21919. PMID:22038899.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, Thomsen OE, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: Post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014;109(7):1055–64. doi:10.1038/ajg.2014.106. PMID:24796769.
   PubMed Web of Science ®Google Scholar